Difficile-Associated Diarrhea Treatment Global Market Report 2024

The global difficile-associated diarrhea treatment market has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to prevalence of hospital-acquired infections, aging population, increasing prevalence of clostridium difficile infections, increasing urbanization.

The global difficile-associated diarrhea treatment market is expected to see rapid growth in the next few years. It will grow to $5.16 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to patient awareness, emerging therapies, global health initiatives, increasing demand for antimicrobial therapy, climate change, demand for self-administered treatments. Major trends in the forecast period include personalized treatment, telemedicine for follow-up, research into novel therapies, advancements in diagnostic techniques.

The increasing prevalence of digestive disorders is poised to act as a driving force behind the growth of the market for treating Clostridium difficile-associated diarrhea. Digestive disorders encompass a group of medical conditions that disrupt the normal functioning of the digestive system, responsible for the breakdown of food and the absorption of nutrients. Clostridium difficile (C. diff) infection is closely linked to digestive disorders, particularly diarrhea and colitis. This bacterium, Clostridium difficile, infects the bowel by producing toxins that induce inflammation and damage the intestinal lining. As more individuals are diagnosed with digestive disorders, there is a growing demand for effective treatments to manage symptoms associated with Clostridium difficile-associated diarrhea. For instance, as of June 2023, data from Crohn's and Colitis Canada, a non-profit organization based in Canada, indicated that an estimated 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting approximately 0.82% of the population. Additionally, projections suggest that around 470,000 Canadians will be living with IBD by 2035, representing about 1.1% of the population, or approximately 1 in every 91 individuals in the country. Consequently, the rising prevalence of digestive disorders is expected to drive the growth of the Clostridium difficile-associated diarrhea treatment market.

The growing prevalence of Clostridium difficile infection (CDI) is anticipated to be a key driver of the expansion of the market for treating Clostridium difficile-associated diarrhea. Clostridium difficile infection, or CDI, is attributed to the bacterium Clostridium difficile, which predominantly affects the colon, produces toxins that harm the colon lining, and leads to symptoms such as diarrhea, abdominal pain, and potentially life-threatening complications. CDI serves as the primary cause of Clostridium Difficile-Associated Diarrhea (DAD), and effectively managing CDI is imperative for addressing and resolving DAD. For instance, as of January 2023, data from the National Library of Medicine, a US-based medical library under the federal government, reported estimates from the Centers for Disease Control (CDC) indicating that approximately half a million Americans are afflicted by C. difficile infection annually. Among these cases, an estimated 29,000 patients experience fatal outcomes within one month of diagnosis, with 15,000 of these deaths directly linked to C. difficile infection. Additionally, about 83,000 patients encounter at least one recurrence of the disease, with 29,000 succumbing to the initial diagnosis within 30 days. Therefore, the escalating prevalence of Clostridium difficile infection is projected to drive the growth of the Clostridium difficile-associated diarrhea treatment market.

The high costs associated with treatments are impeding the growth of the market for treating difficile-associated diarrhea during the forecast period. These elevated treatment expenses can place limitations on patient access to CDAD therapies, particularly affecting individuals lacking adequate health insurance coverage or residing in regions with limited healthcare resources. This reduced accessibility reduces the potential patient pool and dampens market demand. For example, as of January 2023, data from the National Library of Medicine, a US-based medical library, revealed that patients experiencing recurrent Clostridium difficile infection (rCDI) incurred significantly higher total direct costs for all causes, ranging from $132,000 to $207,000, compared to individuals without recurrent CDI, who had total costs of $71,980. Hence, the high treatment costs are serving as an obstacle to the growth of the difficile-associated diarrhea treatment market.

Prominent companies in the difficile-associated diarrhea treatment market are actively engaged in the development of innovative drugs and securing their approvals to maintain their market position. The approval of novel drugs for treating difficile-associated diarrhea is witnessing a significant upsurge due to the growing demand for more effective and safer treatment options. Notably, drugs like SER-109 are paving the way for innovative solutions in difficile-associated diarrhea treatment. For instance, in April 2023, the U.S. Food and Drug Administration (FDA), a federal agency based in the United States, granted approval for SER-109. SER-109 represents the first orally administered fecal microbiota product endorsed for preventing the recurrence of Clostridioides difficile diarrhea. This groundbreaking medication is developed by Seres Therapeutics, a biotechnology company headquartered in the United States. SER-109 is a live, spore-form probiotic that comes in capsule form. It comprises Firmicutes bacteria, which are naturally present in the human gut. The mechanism of SER-109 involves restoring the balance of bacteria in the stomach, thus aiding in the prevention of recurrent C. difficile infections. This innovative medication is designed to prevent the recurrence of Clostridioides difficile (C. diff) infection in individuals aged 18 and above who have undergone antibacterial treatment. The approval of such drugs is poised to transform the landscape of difficile-associated diarrhea treatment.

In April 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company headquartered in the United Kingdom, completed the acquisition of Custopharm Inc. for a sum of $375 million. This strategic acquisition is expected to bolster Hikma Pharmaceuticals PLC's research and development capabilities and pipeline, while also expanding its distinctive US portfolio to include nearly 130 commercially available injectable drugs. Custopharm Inc., based in the United States, specializes in generic sterile injectables production, with a focus on vancomycin, a medication used to treat Clostridium difficile-associated diarrhea (CDAD). This move solidifies Hikma Pharmaceuticals' presence and offerings in the US market.

Major players in the difficile-associated diarrhea treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A.

North America was the largest region in the difficile-associated diarrhea treatment market in 2023. The regions covered in difficile-associated diarrhea treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the difficile-associated diarrhea treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of treatments for C. difficile-associated diarrhea include narrow-spectrum antibiotics and broad-spectrum antibiotics. Narrow-spectrum antibiotics are a class of antimicrobial agents designed to target specific bacterial groups or subgroups. These treatments are accessible through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and serve diverse end users, such as hospitals, homecare, specialty clinics, and more.

This report provides difficile-associated diarrhea treatment market statistics, including difficile-associated diarrhea treatment industry global market size, regional shares, competitors with a difficile-associated diarrhea treatment market share, detailed difficile-associated diarrhea treatment market segments, market trends and opportunities and any further data you may need to thrive in the difficile-associated diarrhea treatment industry. This difficile-associated diarrhea treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The difficile-associated diarrhea treatment market consists of revenues earned by entities by providing conservative therapy, laboratory tests, colonoscopy and imaging tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The difficile-associated diarrhea treatment market also includes sales of oral rehydration solutions, electrolyte supplements and probiotics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.